Browse Studies — Arctuva

Phase 3

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa

The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 y…

Epidermolysis Bullosa (EB)

Estimated

~$10 – $8,750

Paradigm TherapeuticsNCT07482787

Observational

Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions

This is a prospective, single-center, crossover study comparing EndoFLIP measurements obtained in two patient positions, supine and left lateral decubitus, in …

DysphagiaEsophageal StrictureEpidermolysis Bullosa (EB)+3 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07780981

Phase 2

A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa

This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel i…

Epidermolysis Bullosa (EB)Dystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa

Estimated

~$10 – $7,500

Xinnate ABNCT06594393

Phase 1

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Ep…

Epidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaRecessive Dystrophic Epidermolysis Bullosa+1 more

Estimated

~$10 – $7,500

M. Peter MarinkovichNCT07011589